Big R&D investment, but little payoff for drug firms last year

01/11/2006 | NYTimes.com

Despite a $38 billion investment in drug development last year, drug companies saw just 20 new drugs approved by the FDA, down from 36 in 2004. Medical researchers reported significant progress in their search for new treatments, but advances in laboratories have not yet translated into the development and marketing of new drugs. The FDA is looking for ways to speed approvals of new drugs, but consumer groups and some members of Congress are pushing for more testing before drugs are approved.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate General Counsel Business Law
Takeda Pharmaceuticals
Cambridge, MA
Quality Engineer
BiOM
Bedford, MA
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA